Europe – EMA Management Board – highlights of March 2020 meeting

EMA’s first Management Board meeting of 2020 was held virtually in view of the rapidly changing situation in the context of the COVID-19 pandemic. The Board was shortened to one and a half hours to allow EMA and Member States to continue to focus resources on the response to the pandemic.

EMA has now invoked its Business Continuity Plan (BCP) to allow the Agency to manage the pandemic. The plan aims to safeguard the Agency’s core activities and to ring-fence resources that are needed to deal with COVID-19.

Most EMA staff are now working remotely. Despite the reduction in the physical presence of staff at the Agency’s premises, EMA’s core activities in relation to the authorisation and supervision of medicines continue in phase 1 of the EMA COVID-19 BCP. In addition, EMA’s scientific committees, working parties and certain stakeholder events will, for the time being, take place virtually until the end of April 2020…